Apolipoprotein E4 and its later-life health effects on the multiple sclerosis population [0.03%]
载脂蛋白E4及其对多发性硬化病患者晚年健康的影响
Dean Zeldich,Chia Hsin Cheng,Yi Guan et al.
Dean Zeldich et al.
Background and objectives: Multiple sclerosis (MS) is a chronic autoimmune disease causing neuroinflammation and neurodegeneration. The apolipoprotein E4 (APOE4) allele, a major genetic risk factor for late-onset Alzheime...
The impact of relapse on patient disability, clinical outcomes, and subsequent burdens to patients with neuromyelitis optica spectrum disorder and caregivers [0.03%]
NMOSD复发对患者残疾、临床结局和照护者负担的影响
Saif Huda,Martin Kleman,Karl-Johan Myren et al.
Saif Huda et al.
Background: As knowledge is limited about the real-world impact of relapse among patients with neuromyelitis optica spectrum disorder (NMOSD), we aimed to assess the impact of relapse(s) on patient disability, clinical ou...
Setting priorities for how future research in multiple sclerosis in Canada considers equity, diversity and inclusion: A modified e-Delphi study [0.03%]
加拿大未来多发性硬化症研究中如何考虑公平、多样性和包容性的优先事项设定：一种改良的e-德尔菲研究
Ruth Ann Marrie,Afolasade Fakolade,Colleen J Maxwell et al.
Ruth Ann Marrie et al.
Background: Research studies in multiple sclerosis (MS) lack diversity. Objective: To gain consensus on priorities about how future res...
Leptomeningeal enhancement in multiple sclerosis demonstrates posterior predilection and T1 alterations in the adjacent cortex [0.03%]
多发性硬化脑膜炎的强化以后部偏侧为主且临近皮层T1发生变化
Ashley A Thommana,Erin S Beck,Matthew A Greenwald et al.
Ashley A Thommana et al.
Background: Leptomeningeal enhancement (LME) is a putative magnetic resonance imaging (MRI) marker of meningeal inflammation in multiple sclerosis (MS). 3D inversion-prepared fast-spin-echo sequence with real-reconstructi...
Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland [0.03%]
芬兰新发多发性硬化症患者的合并症：一项基于登记的全国人群研究
Henrik Ahvenjärvi,Johanna Krüger,Matias Viitala et al.
Henrik Ahvenjärvi et al.
Background: Comorbidities are common among people with multiple sclerosis (pwMS) and have been suggested to affect the usage of disease-modifying treatments (DMTs). ...
Association of treatment decision with personality, coping strategies and impulsivity in patients with multiple sclerosis [0.03%]
多发性硬化症患者的治疗决策与人格、应对策略和冲动性的相关性分析
Jan Philipp Nolte,Fabian Föttinger,Nik Krajnc et al.
Jan Philipp Nolte et al.
Introduction: Shared decision-making is advocated in treating patients with multiple sclerosis (pwMS), enabled by the wide range of disease-modifying treatments (DMTs). However, the role of psychological characteristics i...
T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3 + CD20+ cells [0.03%]
奥法木单抗治疗的多发性硬化患者T淋巴细胞减少：考虑CD3+CD20+细胞的情况下
Masami Tanaka,Masako Kinoshita,Keiko Tanaka
Masami Tanaka
Background: B cell depleting therapy has become a cornerstone in disease-modifying treatments for relapsing-remitting multiple sclerosis (RRMS). Given that the maximum blood concentration of ofatumumab (OFA) is two orders...
Evan Madill,Brian Healy,Mariann Polgar-Turcsanyi et al.
Evan Madill et al.
Background: Age and sex were shown to influence multiple sclerosis (MS) relapse activity in the 1990s. Whether relapse risk factors are the same with new treatment paradigms is unclear. We evaluate predictors of clinical ...
How do neurologists perceive the organization and functioning of multiple sclerosis care units? [0.03%]
神经学家如何认识多发性硬化症护理单位的组织和运作？
Lamberto Landete,Rocío Gómez-Ballesteros,Virginia Meca-Lallana et al.
Lamberto Landete et al.
This study assessed how neurologists perceive the organization and functioning of multiple sclerosis care units. As a cross-sectional, observational study conducted in collaboration with the Spanish Society of Neurology, an electronic surve...
Cortico-hippocampal molecular characterization in rat model of multiple sclerosis: Neuroprotective mechanisms of Nigella sativa oil [0.03%]
神经保护机制的尼格里亚莎油对多发性硬化大鼠模型的皮层海马分子表征的研究
Rhoda Mama Kolo,Chijoke Bethel Ehirim,Damilola Opeadua Olabiyi et al.
Rhoda Mama Kolo et al.
Background: Current multiple sclerosis management primarily targets symptom alleviation and immune modulation, with limited success in halting progression or achieving sustained remission. Consequently, the development of...